Company Overview and News

 
TDC / Teradata Corp. FORM 8-K (Current Report)

2018-04-23 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
TDC / Teradata Corp. / Bank of New York Mellon Corp - null (Passive Investment)

2018-04-20 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2)* NAME OF ISSUER: Teradata Corporation TITLE OF CLASS OF SECURITIES: Common Stock CUSIP NUMBER: 88076W103 DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT: March 31, 2018 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclos
Upvote Downvote

 
TDC / Teradata Corp. / Bank of New York Mellon Corp - null (Passive Investment)

2018-04-20 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2)* NAME OF ISSUER: Teradata Corporation TITLE OF CLASS OF SECURITIES: Common Stock CUSIP NUMBER: 88076W103 DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT: March 31, 2018 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclos
Upvote Downvote

 
Factors Affecting Teradata’s Bottom-Line Growth

2018-03-28 editors.aws.marketrealist
Teradata Corporation’s (TDC) bottom line has been affected by the higher investment related to shifting to the subscription-based model from its tradition upfront model. The new business model also reduced the upfront revenues earned in fiscal 2016, resulting in lower EPS (earnings per share).
Upvote Downvote

 
RBC Sees 4 Software Stocks as Potential Takeover Candidates

2018-03-20 247wallst
It happens every year, and 2018 won’t be any different. Larger companies looking to add to growth, in addition to that of the organic or internal variety, scan the field for purchases and acquisitions that are easy to bolt on and could add returns in a timely fashion. This year the process may even speed up some as last month’s market sell-off may already have put some companies in the sights of acquirers.
Upvote Downvote

 
TDC / Teradata Corp. DEFA14A

2018-03-12 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
Teradata (TDC) Up 3.7% Since Earnings Report: Can It Continue?

2018-03-12 zacks
A month has gone by since the last earnings report for Teradata Corporation (TDC - Free Report) . Shares have added about 3.7% in that time frame.
Upvote Downvote

 
TDC / Teradata Corp. DEFR14A

2018-03-09 sec.gov
DEFR14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A
Upvote Downvote

 
TDC / Teradata Corp. DEF 14A

2018-03-07 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A
Upvote Downvote

 
Cisco, Teradata Collaborate to Digitally Transform Cities

2018-03-06 zacks
Cisco Systems, Inc. (CSCO - Free Report) and Teradata Corp. (TDC - Free Report) recently collaborated to leverage on IoT with a view to digitally transform cities. Integration of Cisco’s Kinetic IoT data platform with Teradata Analytics Platform enhances support for public safety and will aid in creating smart city framework. This new platform is aimed to provide solution for integrated data exchange.
Upvote Downvote

2
Top Analyst Upgrades and Downgrades: AMAG, Foot Locker, Groupon, H&R Block, McDonald’s, Teradata, Under Armour, Valeant and More

2018-03-05 247wallst
Stocks were indicated marginally lower on Monday morning, with more worries of trade wars after steel and aluminum tariffs. The Dow Jones industrial average was indicated to open under 24,500 and the S&P 500 was indicated to open under 2,685. The bull market is turning nine years old this week, and the one trend that has prevailed has been for investors to buy the pullbacks. Investors have to decide how they want to be positioned for the rest of 2018 and beyond.
Upvote Downvote

 
TDC / Teradata Corp. TERADARA 2017 10-K (Annual Report)

2018-02-23 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
HPE Stock Price - Hewlett Packard Enterprise Co. Stock Quote (U.S.: NYSE) - MarketWatch

2018-02-22 marketwatch
Meg Whitman has taken the chief executive officer job at NewTV, one of Jeffrey Katzenberg's WndrCo LLC portfolio companies, the company said Wednesday. Whitman has previously run Hewlett Packard Enterprise Co. and eBay Inc. NewTV is the company's working name. Whitman stepped down from HPE in November, after a six-year tenure with the company where she promised to turn the business around, and including splitting the company into two parts in 2014.
Upvote Downvote

 
Teradata: A Misinterpretation Of A Robust Quarter

2018-02-13 seekingalpha
Some analysts were unhappy because the company sold too much in the way of product and perpetual license.
Upvote Downvote

 
Teradata (TDC) Q4 Earnings Top, Shares Fall on Flat Revenues

2018-02-12 zacks
Shares of Teradata Corporation (TDC - Free Report) plunged almost 6.2% to close at $35 on Feb 9, following dismal fourth-quarter 2017 results. Adjusted earnings of 58 cents per share declined 17.1% year over year. However, the figure beat the Zacks Consensus Estimate of 50 cents. Total revenues of $626 million beat the Zacks Consensus Estimate of $610 million. However, the figure was flat on a year-over-year basis.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

CUSIP: 88076W103